• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Helix Announces Peer-Review Publication of V-DOS47 in Frontiers in Immunology Journal

    Bryan Mc Govern
    Aug. 22, 2017 09:23AM PST
    Biotech Investing

    Helix BioPharma shared the publication of a peer-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal.

    Helix BioPharma (TSX:HBP) shared the publication of a peer-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal.
    As quoted in the press release:

    V-DOS47 is Helix’s second DOS47 development candidate following L-DOS47, which is currently in clinical testing for the treatment of non-small cell lung cancer.
    The article, entitled “Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2”, describes the design and construction of V-DOS47 for breast cancer and other potential indications. The paper can be accessed online at https://doi.org/10.3389/fimmu.2017.00956.
    “We are very pleased to present our V-DOS47 research work through a peer-reviewed forum,” said Heman Chao, Ph.D., Chief Executive & Scientific Officer of Helix. “V-DOS47 research and development activities, coordinated by our Polish subsidiary, Helix Immuno-Oncology S.A., have been progressing well. We continue to work closely with our team in Poland to advance the DOS47 platform.”

    Click here to read the full press release.

    Source: www.marketwired.com

    clinical testingbreast cancernon small cell lung cancerhelix biopharma
    The Conversation (0)

    Go Deeper

    AI Powered

    FDA Confirms IND Application From VBI Vaccines

    Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES